Navigation Links
Savara Closes Series A Financing Round
Date:6/9/2009

- Funds Raised Will Be Used to Expand Technology into New Pulmonary Markets -

AUSTIN, Texas, June 9 /PRNewswire/ -- Savara Pharmaceuticals, a biotechnology inhalation drug delivery company, today announced that it has closed its Series A financing round.

The majority of Savara's existing investors participated in the round, which was made up of biotechnology industry veterans and successful business leaders. Savara will utilize the funds to continue development of its NanoCluster technology in the dry powder therapeutics market and expand into nebulizer and propellant markets.

"I'm excited that we exceeded our entire Series A fund raising goal in just a few weeks," said Rob Neville, Savara's Executive Chairman. "The funds from our seed round allowed us to validate our technology across multiple drug classes, which led to several partnerships with large pharmaceutical companies. We've assembled a world class team and are ready to pursue the numerous opportunities ahead of us."

Savara has the option to complete a second tranche of the Series A round later this year if additional funds are needed.

The key parameter to improving the efficacy of pulmonary products depends on being able to dial-in particles sizes in the range of one to three microns. The Savara NanoCluster technology has this capability without the need for novel excipients and benefits from a highly efficient manufacturing process. These NanoClusters are modeled after naturally occurring aerosols, which are highly effective in reaching the peripheral lung.

About Savara

Savara Pharmaceuticals, (www.savarapharma.com) develops next generation pulmonary drug delivery solutions using its NanoCluster formulation technology. Dry powder and nebulizer-based medicines are formulated directly from active drug ingredients, requiring no carrier particles and little or no excipients. The aerodynamics of NanoCluster formulations are fully customizable from one to seven microns enabling high drug concentrations at specific regions of the lung, independent of the rate or depth of breath. Savara expects that NanoCluster's unique features will produce numerous patient benefits including reduced dosage, enhanced efficacy, improved safety and increased tolerability, as well as greater patient convenience. Savara's NanoCluster technology is currently available for evaluation and licensing.

CONTACT: Ian M. Stone for Savara Pharmaceuticals, +1-619-528-2220, ian.stone@russopartnersllc.com


'/>"/>
SOURCE Savara Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Response Biomedical Closes $12.65 million Unit Offering
2. Swine Flu Closes Three Schools in NYC
3. Swine Flu Closes 3 Schools in NYC
4. Aethlon Medical Discloses New HIV/AIDS Treatment Data
5. ASA May Day - Stung By Exposure of Watergate-like Public Record Deletions, American Society of Anesthesiologists Closes Access to Website Newsletter
6. Providence Service Corporation to Report First Quarter 2009 Results on Wednesday, May 6th After the Market Closes
7. PhotoThera Closes $50 Million Financing, Announces New President and Chief Executive Officer
8. ProAssurance Closes PICA Transaction
9. Conseco Closes Amendment to Credit Facility
10. ReGear Life Sciences Closes $2.5 Million in Series A Financing Following $1M Investment by Stonewood Capital Management, Inc.
11. GetWellNetwork Closes $10 Million Financing, Eight Hospitals Choose PatientLife System(R) for Unparalleled Patient Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... 04, 2016 , ... Momsense, Inc. has developed ... patented technology, The Smart Breastfeeding Meter, is designed to monitor and measure a ... now available for purchase at Target.com . , Breastfeeding is a ...
(Date:5/4/2016)... ... 04, 2016 , ... Recognizing that lifestyle medicine is essential to health and ... tapped David Katz, MD, MPH, president of the American College of Lifestyle Medicine, as ... is especially gratifying,” said Katz. “There is so much opportunity to add years to ...
(Date:5/4/2016)... ... 2016 , ... Natalie Jill is a well respected lifestyle mentor ... the launch of her new book: Natalie Jill’s 7 Day Jump Start: Unprocess Your ... jump start a new healthy lifestyle featuring simple recipes using MitoXcell’s raw cacao formula. ...
(Date:5/4/2016)... , ... May 04, 2016 , ... The preeminent surgical ... Janice Dickinson needed following breast cancer surgery. In March 2016, the 61-year-old model and ... of breast cancer that occurs in the milk ducts, according to an interview ...
(Date:5/4/2016)... ... ... Advanced Spine & Sport Medical Rehabilitation Center, which is renowned for its use ... on stem cell injections. The seminar is scheduled for Wednesday, May 18, from 6-8 ... 110, Ventura, CA. There are only 10 seats available. , “The purpose of ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... Research and Markets has ... Myeloma Market and Competitive Landscape Highlights - ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ... Highlights 2016, provides comprehensive insights into Multiple ... Myeloma market valuations and forecast, Multiple Myeloma ...
(Date:5/3/2016)... 2016 Global Insulin Needles ... 09 key companies and supported with 272 tables ... study on the current state of the Insulin ... industry including definitions, classifications, applications and industry chain ... for the international market including development history, competitive ...
(Date:5/3/2016)... ACME Markets, Delaware County ... Councilman Dave White announced today the availability ... pharmacies across Delaware County . According ... has saved 26,463 lives nationwide over the past 20 years. Since ... were authorized to administer naloxone to overdose victims, 244 lives ...
Breaking Medicine Technology: